About Us | Contact

Dr. Frederick R Behringer JR. Investigator

MOHS-Micrographic Surgery NPI1043218860
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$10,889.60
from 17 payments in the last 6 years

Total Cash or Cash Equivalent

$10,055.29
from 6 payments in the last 6 years

Total In-kind Items & Services

$834.31
from 11 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
06/10/2021 General (Non-Research) In-kind items and services Food and Beverage $22.40 Details
Payment from SUN PHARMACEUTICAL INDUSTRIES INC.
Payment Record ID 851881625
09/02/2021 General (Non-Research) In-kind items and services Food and Beverage $19.61 Details
Payment from AbbVie Inc.
Payment Record ID 794024175
03/04/2021 General (Non-Research) In-kind items and services Food and Beverage $26.34 Details
Payment from AbbVie Inc.
Payment Record ID 794024171
08/24/2020 General (Non-Research) In-kind items and services Food and Beverage $14.64 Details
Payment from AbbVie Inc.
Payment Record ID 721693911
01/16/2019 General (Non-Research) Cash or cash equivalent Food and Beverage $18.99 Details
Payment from DUSA Pharmaceuticals, Inc.
Payment Record ID 704619589
11/07/2019 General (Non-Research) In-kind items and services Food and Beverage $13.82 Details
Payment from PFIZER INC.
Payment Record ID 673756203
10/14/2019 General (Non-Research) In-kind items and services Food and Beverage $20.79 Details
Payment from AbbVie, Inc.
Payment Record ID 648007251
08/23/2018 General (Non-Research) In-kind items and services Food and Beverage $22.45 Details
Payment from DUSA Pharmaceuticals, Inc.
Payment Record ID 616608334
12/28/2018 Research Cash or cash equivalent Drug $750.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A MULTICENTER STUDY WITH A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED MAINTENANCE DOSING PERIOD AND A LONG TERM EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF LY2439821 IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Clinical Trials Gov ID NCT01474512
Payment Record ID 585602227
12/11/2018 Research Cash or cash equivalent Drug $4096.80 Details
Payment from Eli Lilly and Company
Paymment Research Study A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD
Clinical Trials Gov ID NCT01646177
Payment Record ID 585602225
01/18/2016 General (Non-Research) In-kind items and services Food and Beverage $17.85 Details
Payment from Genentech USA, Inc.
Payment Record ID 513177537
03/02/2017 General (Non-Research) In-kind items and services Food and Beverage $19.84 Details
Payment from LEO Pharma Inc.
Payment Record ID 499324373
01/12/2017 Research Cash or cash equivalent Drug $650.00 Details
Payment from Sandoz Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO DEMONSTRATE EQUIVALENT EFFICACY AND TO COMPARE SAFETY AND IMMUNOGENICITY OF A BIOSIMILAR ADALIMUMAB (GP2017) AND HUMIRA? IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASIS
Payment Record ID 483258941
08/28/2017 Research In-kind items and services Drug $641.90 Details
Payment from Eli Lilly and Company
Paymment Research Study A MULTICENTER STUDY WITH A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED MAINTENANCE DOSING PERIOD AND A LONG TERM EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF LY2439821 IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Clinical Trials Gov ID NCT01474512
Payment Record ID 457096985
11/08/2016 General (Non-Research) In-kind items and services Education $14.67 Details
Payment from Actelion Pharmaceuticals US, Inc.
Payment Record ID 413272592
02/18/2016 Research Cash or cash equivalent Drug $3801.90 Details
Payment from Sandoz Inc.
Paymment Research Study A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Payment Record ID 386566924
01/27/2016 Research Cash or cash equivalent Drug $737.60 Details
Payment from Sandoz Inc.
Paymment Research Study A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Payment Record ID 386566915
;